EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
Journal
Future Oncology
Journal Volume
9
Journal Issue
7
Pages
991-1003
Date Issued
2013
Author(s)
Abstract
Drugs that target the EGFR have a major impact on the treatment of advanced non-small-cell lung cancer (NSCLC). EGFR mutations in NSCLC are associated with a dramatic and sustained response to EGFR tyrosine kinase inhibitors (TKIs). This review summarizes the results of randomized trials using EGFR TKIs or EGFR monoclonal antibodies with chemotherapy in the first-line setting, and discusses several unresolved issues regarding the use of the EGFR TKIs as the first-line therapy in advanced NSCLC. ? 2013 Future Medicine Ltd.
SDGs
Other Subjects
4 [4 (4' chloro 2 biphenylylmethyl) 1 piperazinyl] n [4 [3 dimethylamino 1 (phenylthiomethyl)propylamino] 3 nitrobenzenesulfonyl]benzamide; afatinib; bevacizumab; bms 099; carboplatin; cetuximab; cisplatin; dacomitinib; docetaxel; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; gemcitabine; navelbine; paclitaxel; pemetrexed; placebo; tivantinib; unclassified drug; advanced cancer; antibody dependent cellular cytotoxicity; antineoplastic activity; apoptosis; binding affinity; cancer chemotherapy; cancer combination chemotherapy; cancer survival; cell proliferation; covalent bond; crystal structure; disease exacerbation; drug cytotoxicity; drug efficacy; drug treatment failure; human; lung adenocarcinoma; lung non small cell cancer; meta analysis (topic); monotherapy; overall survival; personalized medicine; phase 2 clinical trial (topic); phase 3 clinical trial (topic); priority journal; progression free survival; protein expression; quality of life; randomized controlled trial (topic); review; skin toxicity; somatic mutation; statistical significance; systemic therapy; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Receptor, Epidermal Growth Factor
Type
review